Primary care physicians can play a critical role in recognizing transthyretin amyloid cardiomyopathy, initiating an appropriate diagnostic evaluation, coordinating treatment, and helping patients and...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
In a landmark survival analysis of 596 consecutive patients with transthyretin amyloid cardiomyopathy, worsening NT-proBNP and heart failure hospitalization at 6 months were independently associated with...
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...
